Author/Editor		Borovšak, Zvonko; Matkovič-Lonzarić, Nives
Title		Zdravljenje neobvladljive krvavitve z rFVIIa (NovoSevenR) v SB Maribor - naše izkušnje
Translated title		Treatment of uncontrollable hemorrhage with rFVIIa (NovoSevenR) at Maribor teaching hospital - our experience
Type		članek
Source		In: Urlep-Šalinović V, editor. Hemostatske motnje. Strokovno srečanje ob 30-letnici hemostaziološke dejavnosti v Splošni bolnišnici Maribor; 2006 maj 26; Maribor. Maribor: Splošna bolnišnica Maribor,
Publication year		2006
Volume		str. 129-37
Language		slo
Abstract		Recombinant activated factor VII (rFVIIa-NovoSeven) is used to treat lifethreatening uncontrollable hemorrhages that connot be arrested with standard bood preparations. As the range of indications for the application of rFVIIa is widening, that could lead to its inappropriate use. This can only be avoided by careful analysis of patients who had received treatment with rFVIIa. The retrograde analysis included 7 patients treated with rFVIIa at Maribor Teaching Hospital between June 2004 and March 2006. The indication was surgically uncontrollable hemorrhage. All patients were treated previously with standard blood substitutes. rFVIIa was administered in a concentration of 90 mg/kg BW after or during operative revision following a previous urgent and/or programmed operative procedure. Blood samples were taken for hemostasis evaluation before and after treatment with rFVIIa. Two patients were excluded from the analysis due to incomplete documentation. After rFVIIa treatment, prothrombin time nd activated thromboplastin time were both slightly increased, fibrinogen concentration was somewhat increased also while the platelet count had decreased after treatment with rFVIIa. In two patients the hemorrhage had stopped completely, in two patients it decreased significantly, in one patient only no changes were seen. Despite guidelines and recommendations for treatment with rFVIIa, there is not a single blood-coagulation test that could serve as an objective indicator for treatment with rFVIIa. Clinical evaluation is the most frequent basis for decisions regarding treatment with rFVIIa.
Descriptors		HEMORRHAGE FACTOR VIIA RECOMBINANT PROTEINS